RxDoctor Payments Data

Robert Honea, MD

Family Medicine · Reform, ALNPI 1083713556

Payments from drug & device makers

$7,088in general payments, 2019–2025

Across 448 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$968
  • Novartis$730
  • Johnson & Johnson$640
  • Amgen$553
  • Otsuka America Pharmaceutical, Inc.$463
  • Novo Nordisk$422
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,98899%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,088 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$306,401
Medicare patients
283
Services billed
6,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide150$197,771
JardianceEmpagliflozin136$128,867
EliquisApixaban120$107,387
JanuviaSitagliptin Phosphate96$102,121
OzempicSemaglutide86$92,485
TradjentaLinagliptin125$90,335
XareltoRivaroxaban70$67,146
LinzessLinaclotide53$41,636
TrulicityDulaglutide33$39,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$37,472
MyrbetriqMirabegron64$33,840
Repatha SureclickEvolocumab44$30,499
FarxigaDapagliflozin Propanediol27$25,173
EntrestoSacubitril/Valsartan20$20,946
RexultiBrexpiprazole11$18,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$98$236,813183 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$35$233,666288 claims
PfizerEliquis, Abrysvo$246$125,066175 claims
MerckJanuvia$99$102,12196 claims
Novo NordiskOzempic$422$92,48586 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta$159$68,306135 claims
Johnson & JohnsonXarelto$640$67,14670 claims
AbbVieLinzess$968$41,63653 claims
Astellas Pharma US IncMyrbetriq$316$33,84064 claims
AstraZenecaFarxiga, Symbicort$96$33,78558 claims
NovartisEntresto$730$20,94620 claims
Otsuka America Pharmaceutical, Inc.Rexulti$463$18,50211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Reform

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →